EU/3/05/263

Table of contents

About

On 3 March 2005, orphan designation (EU/3/05/263) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for dimethyl sulfoxide for the treatment of severe closed traumatic brain injury.

Key facts

Active substance
Dimethyl sulfoxide
Disease / condition
Treatment of severe closed traumatic brain injury
Date of decision
03/03/2005
Outcome
Positive
Orphan decision number
EU/3/05/263

Sponsor's contact details

AOP Orphan Pharmaceuticals AG
Wilheminenstrasse 91/II/f/5
1160 Wien, Austria
Telephone: +43 1 50 33 72 44
Telefax: +43 1 50 37 24 45
E-mail: office@aoporphan.at

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Headway - National Brain Injury Association
    4 King Edward Court
    King Edward Street
    Nottingham
    NG1 1EW
    United Kingdom
    Telephone: +44 115 92 40 800 / +44 80 88 00 22 44 (helpline)
    E-mail: enquiries@headway.org.uk
  • Headway Ireland
    101 Parnell Street
    Dublin 1
    Ireland
    Telephone: +353 1 87 29 222
    Telefax: +353 1 87 29 590
    E-mail : info@headwayireland.ie
  • Coordinamento Nazionale Associazioni Trauma Cranico
    c/o AMICI dei Traumatizzati Cranici
    via V. Veneto 171
    c/o Ospedale Gorizia
    Gorizia 34171
    Italy
    Telephone: +39 04 81 48 77 20
    Telefax: +39 04 81 48 75 88
    E-mail: protezioneaz@ass2.sanita.fvg.it

How useful was this page?

Add your rating